News Archive
AMHN, Inc., parent company of America's Minority Health Network, Inc., announced today that its network reached its first milestone by completing its 100th installation. America's Minority Health Network, Inc. is a place-based provider of digital video education for medical practices that primarily serve minorities.
Most dentists are good clinicians, but it's the business side of running a practice that stresses them the most and limits their success in the profession. Many of the troubling issues that dentists deal with in their practice are explored in a new book, A Drive to Excellence: Building a High Performance, Patient-Centered Dental Practice.
A drug that blocks production of an enzyme that enables ovarian cancer to gain a foothold in a new site can slow the spread of the disease and prolong survival in mice, according to a study by researchers from the University of Chicago Medical Center, but only if the drug is given early in the disease process.
Semafore Pharmaceuticals today reported encouraging data from a Phase I dose-escalation trial of SF1126 in patients with relapsed and refractory myeloma. SF1126 is a novel small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mammalian target of rapamycin (mTOR), two key members of the PI3K signaling pathway that is vital to several essential biological processes, such as cell proliferation and survival. PI3K is commonly altered in human cancers, making inhibition of the target attractive for cancer therapy.
Researchers at the Israel Institute of Technology have found that children's mattresses may represent a health hazard as they emit some dangerous pollutants at concerning levels overnight.
› Verified 8 days ago